Literature DB >> 22291010

4-(4-(dimethylamino)phenyl)-1-methylpyridinium (APP+) is a fluorescent substrate for the human serotonin transporter.

Ernesto Solis1, Igor Zdravkovic, Ian D Tomlinson, Sergei Y Noskov, Sandra J Rosenthal, Louis J De Felice.   

Abstract

Monoamine transporters terminate synaptic neurotransmission and are molecular targets for antidepressants and psychostimulants. Fluorescent reporters can monitor real-time transport and are amenable for high-throughput screening. However, until now, their use has mostly been successful to study the catecholamine transporters but not the serotonin (5HT) transporter. Here, we use fluorescence microscopy, electrophysiology, pharmacology, and molecular modeling to compare fluorescent analogs of 1-methyl-4-phenylpyridinium (MPP(+)) as reporters for the human serotonin transporter (hSERT) in single cells. The fluorescent substrate 4-(4-(dimethylamino)phenyl)-1-methylpyridinium (APP(+)) exhibits superior fluorescence uptake in hSERT-expressing HEK293 cells than other MPP(+) analogs tested. APP(+) uptake is Na(+)- and Cl(-)-dependent, displaced by 5HT, and inhibited by fluoxetine, suggesting APP(+) specifically monitors hSERT activity. ASP(+), which was previously used to study catecholamine transporters, is 10 times less potent than APP(+) at inhibiting 5HT uptake and has minimal hSERT-mediated uptake. Furthermore, in hSERT-expressing oocytes voltage-clamped to -60 mV, APP(+) induced fluoxetine-sensitive hSERT-mediated inward currents, indicating APP(+) is a substrate, whereas ASP(+) induced hSERT-mediated outward currents and counteracted 5HT-induced hSERT currents, indicating ASP(+) possesses activity as an inhibitor. Extra-precise ligand receptor docking of APP(+) and ASP(+) in an hSERT homology model showed both ASP(+) and APP(+) docked favorably within the active region; accordingly, comparable concentrations are required to elicit their opposite electrophysiological responses. We conclude APP(+) is better suited than ASP(+) to study hSERT transport fluorometrically.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22291010      PMCID: PMC3308769          DOI: 10.1074/jbc.M111.267757

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  70 in total

1.  Novel fluorescence-based approaches for the study of biogenic amine transporter localization, activity, and regulation.

Authors:  J N Mason; H Farmer; I D Tomlinson; J W Schwartz; V Savchenko; L J DeFelice; S J Rosenthal; R D Blakely
Journal:  J Neurosci Methods       Date:  2004-11-28       Impact factor: 2.390

Review 2.  The functional impact of SLC6 transporter genetic variation.

Authors:  Maureen K Hahn; Randy D Blakely
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

Review 3.  Bioenergetics of neurotransmitter transport.

Authors:  G Rudnick
Journal:  J Bioenerg Biomembr       Date:  1998-04       Impact factor: 2.945

4.  Serotonin transporter function and pharmacology are sensitive to expression level: evidence for an endogenous regulatory factor.

Authors:  I Scott Ramsey; Louis J DeFelice
Journal:  J Biol Chem       Date:  2002-02-13       Impact factor: 5.157

5.  Pharmacological characterization of a fluorescent uptake assay for the noradrenaline transporter.

Authors:  Anders Haunsø; Dawn Buchanan
Journal:  J Biomol Screen       Date:  2007-03-22

6.  Localization of mitochondria in living cells with rhodamine 123.

Authors:  L V Johnson; M L Walsh; L B Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1980-02       Impact factor: 11.205

7.  D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism.

Authors:  Elizabeth A Bolan; Bronwyn Kivell; Vanaja Jaligam; Murat Oz; Lankupalle D Jayanthi; Yang Han; Namita Sen; Eneki Urizar; Ivone Gomes; Lakshmi A Devi; Sammanda Ramamoorthy; Jonathan A Javitch; Agustin Zapata; Toni S Shippenberg
Journal:  Mol Pharmacol       Date:  2007-01-31       Impact factor: 4.436

Review 8.  Selective serotonin re-uptake inhibitors in anorexia nervosa.

Authors:  Meera Vaswani; Harish Kalra
Journal:  Expert Opin Investig Drugs       Date:  2004-04       Impact factor: 6.206

9.  Antidepressant binding site in a bacterial homologue of neurotransmitter transporters.

Authors:  Satinder K Singh; Atsuko Yamashita; Eric Gouaux
Journal:  Nature       Date:  2007-08-08       Impact factor: 49.962

10.  Monitoring of relative mitochondrial membrane potential in living cells by fluorescence microscopy.

Authors:  L V Johnson; M L Walsh; B J Bockus; L B Chen
Journal:  J Cell Biol       Date:  1981-03       Impact factor: 10.539

View more
  19 in total

Review 1.  The vesicular monoamine transporter 2: an underexplored pharmacological target.

Authors:  Alison I Bernstein; Kristen A Stout; Gary W Miller
Journal:  Neurochem Int       Date:  2014-01-04       Impact factor: 3.921

2.  Electrical coupling between the human serotonin transporter and voltage-gated Ca(2+) channels.

Authors:  Iwona Ruchala; Vanessa Cabra; Ernesto Solis; Richard A Glennon; Louis J De Felice; Jose M Eltit
Journal:  Cell Calcium       Date:  2014-04-27       Impact factor: 6.817

3.  An N-terminal threonine mutation produces an efflux-favorable, sodium-primed conformation of the human dopamine transporter.

Authors:  Rheaclare Fraser; Yongyue Chen; Bipasha Guptaroy; Kathryn D Luderman; Stephanie L Stokes; Asim Beg; Louis J DeFelice; Margaret E Gnegy
Journal:  Mol Pharmacol       Date:  2014-04-21       Impact factor: 4.436

4.  N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability.

Authors:  Ernesto Solis; John S Partilla; Farhana Sakloth; Iwona Ruchala; Kathryn L Schwienteck; Louis J De Felice; Jose M Eltit; Richard A Glennon; S Stevens Negus; Michael H Baumann
Journal:  Neuropsychopharmacology       Date:  2017-05-22       Impact factor: 7.853

5.  Interactions between Cocaine and the Putative Allosteric Dopamine Transporter Ligand SRI-31142.

Authors:  Megan J Moerke; Subramaniam Ananthan; Matthew L Banks; Jose M Eltit; Kelen C Freitas; Amy R Johnson; Surendra K Saini; Tyler W E Steele; S Stevens Negus
Journal:  J Pharmacol Exp Ther       Date:  2018-08-27       Impact factor: 4.030

6.  New fluorescent substrate enables quantitative and high-throughput examination of vesicular monoamine transporter 2 (VMAT2).

Authors:  Gang Hu; Adam Henke; Richard J Karpowicz; Mark S Sonders; Frances Farrimond; Robert Edwards; David Sulzer; Dalibor Sames
Journal:  ACS Chem Biol       Date:  2013-07-16       Impact factor: 5.100

7.  Binding-induced fluorescence of serotonin transporter ligands: A spectroscopic and structural study of 4-(4-(dimethylamino)phenyl)-1-methylpyridinium (APP(+)) and APP(+) analogues.

Authors:  James N Wilson; Lucy Kate Ladefoged; W Michael Babinchak; Birgit Schiøtt
Journal:  ACS Chem Neurosci       Date:  2014-02-05       Impact factor: 4.418

8.  APP+, a fluorescent analogue of the neurotoxin MPP+, is a marker of catecholamine neurons in brain tissue, but not a fluorescent false neurotransmitter.

Authors:  Richard J Karpowicz; Matthew Dunn; David Sulzer; Dalibor Sames
Journal:  ACS Chem Neurosci       Date:  2013-05-06       Impact factor: 4.418

9.  Functional characterization of N-octyl 4-methylamphetamine variants and related bivalent compounds at the dopamine and serotonin transporters using Ca2+ channels as sensors.

Authors:  Iwona Ruchala; Umberto M Battisti; Vy T Nguyen; Rita Yu-Tzu Chen; Richard A Glennon; Jose M Eltit
Journal:  Toxicol Appl Pharmacol       Date:  2021-03-27       Impact factor: 4.219

10.  Handling of intracellular K+ determines voltage dependence of plasmalemmal monoamine transporter function.

Authors:  Shreyas Bhat; Marco Niello; Klaus Schicker; Christian Pifl; Harald H Sitte; Michael Freissmuth; Walter Sandtner
Journal:  Elife       Date:  2021-06-01       Impact factor: 8.713

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.